Clinical Trial Update: Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the food effect of a fixed-dose combination of daclatasvir, asunaprevir, and BMS-791325 in Hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• BMS-791325
• Daclatasvir (daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED